Gainers

• Apellis Pharmaceuticals (NASDAQ:APLS) shares moved upwards by 138.8% to $40.81 during Tuesday's pre-market session. The company's market cap stands at $2.1 billion.
• Virax Biolabs Group (NASDAQ:VRAX) shares rose 62.43% to $0.26. The market value of their outstanding shares is at $1.2 million.
• Centessa Pharmaceuticals (NASDAQ:CNTA) stock rose 47.49% to $40.68. The market value of their outstanding shares is at $4.0 billion.
• Insight Molecular (NASDAQ:IMDX) stock rose 34.9% to $3.44. The company's market cap stands at $82.0 million. The company's, Q4 earnings came out 3 days ago.
• IM Cannabis (NASDAQ:IMCC) stock increased by 30.19% to $0.53. The market value of their outstanding shares is at $2.4 million.
• Lantern Pharma (NASDAQ:LTRN) stock rose 19.83% to $1.48. The company's market cap stands at $13.8 million. The company's, Q4 earnings came out yesterday.

Losers

• PepGen (NASDAQ:PEPG) shares fell 48.7% to $2.17 during Tuesday's pre-market session. The company's market cap stands at $290.8 million.
• Iterum Therapeutics (NASDAQ:ITRM) stock declined by 32.53% to $0.05. The company's market cap stands at $3.7 million.
• Phreesia (NYSE:PHR) stock fell 24.19% to $8.65. The company's market cap stands at $687.8 million. As per the news, the Q4 earnings report came out yesterday.
• Sangamo Therapeutics (NASDAQ:SGMO) stock fell 16.73% to $0.26. The market value of their outstanding shares is at $114.2 million. As per the news, the Q4 earnings report came out yesterday.
• BioLife Solutions (NASDAQ:BLFS) stock fell 15.87% to $15.8. The company's market cap stands at $899.6 million.
• ImageneBio (NASDAQ:IMA) stock decreased by 14.0% to $4.3. The market value of their outstanding shares is at $55.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.